cartitude-2: evaluating car t therapy cilta-cel in multiple myeloma patients who had early relapse
Published 2 years ago • 340 plays • Length 5:03Download video MP4
Download video MP3
Similar videos
-
4:25
updated results from cartitude-1: phase 1b/2study of cilta-cel in pts with rr multiple myeloma
-
1:45
cartitude-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
-
4:09
are there trials evaluating car t-cell therapy in early disease myeloma patients?
-
4:17
car-t cell therapy cilta-cel for relapsed/refractory myeloma | doris hansen, md | asco 2023
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
3:52
updated results (2 years post-lpi) in phase 1b/2 (cartitude-1) study of cilta-cel in rrmm patients
-
8:45
updates on clinical data of cilta-cel in cartitude-2 cohort a among progressive mm patients
-
4:33
cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
9:34
neurologic adverse effects in pts with mm treated with cilta-cel in cartitude-2
-
4:10
cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma
-
7:23
cartitude-2: efficacy and safety of ciltacabtagene autoleucel in patients with progressive mm
-
3:52
is car t-cell therapy being used to treat newly diagnosed multiple myeloma?
-
11:43
cartitude-4: cilta-cel vs standard of care pvd or dpd in lenalidomide-refractory multiple myeloma
-
5:46
outcomes from the cartitude-1 study assessing car t-cell therapy in rr multiple myeloma
-
3:37
updated data from cartitude-1 and cartitude-2 studies testing cilta-cel in r/r multiple myeloma
-
7:41
cartitude-2: ciltacabtagene autoleucel in patients with progressive multiple myeloma
-
28:19
international myeloma workshop 2021 | daily update, part 2 | car-t cell therapy smoldering mm
-
4:08
the impact of the approval of cilta-cel in multiple myeloma